triplet regimen improves responses in braf v600e metastatic crc
Published 5 years ago • 188 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
7:02
triplet regimens in braf-mutant metastatic crc
-
4:19
targeting braf in metastatic crc
-
6:01
beacon trial: triplet therapy in braf v600e–mutated mcrc
-
1:18
safety lead-in data for beacon crc trial with triplet biologic regimen in mcrc
-
0:54
triplet therapy for certain patients with metastatic crc shows promise, but more research is needed
-
6:06
colorectal cancer debate: first line braf v600e - targeted triplet
-
1:18
how braf v600e-mutated crc is treated differently than other cancers
-
0:49
next steps after phase iii beacon crc trial in mcrc
-
4:54
case 1: braf-mutated metastatic colorectal cancer
-
3:25
first-line triplet in braf mcrc
-
1:32
dr. flaherty on the rationale to explore triplet therapy in braf v600e-mutant melanoma
-
5:19
targeting braf v600e in metastatic colorectal cancer: where are we today?
-
1:09
dr. kopetz on updated data from beacon crc study in braf v600e–mutant crc
-
2:24
real-world management of patients with braf-v600e mcrc
-
8:16
encorafenib & binimetinib cetuximab for untreated braf v600e-mutant metastatic colorectal cancer
-
1:35
scott kopetz, md, shares updates from the beacon trial in braf-mutant colorectal cancer
-
1:11
dr. kopetz on the rationale for the beacon crc study in braf v600e-mutant mcrc
-
20:52
what is the optimal therapy for braf mutant metastatic colorectal cancer?
-
1:17
treatment approaches for braf v600e mutant metastatic colorectal cancer